A plain-language guide

Understanding Neuroendocrine Tumors

A neuroendocrine tumor (NET) diagnosis brings a lot of questions. This page explains, in plain language, what NETs are, how they're tested and treated, and how family and friends can help.

If you hear hoofbeats, think horses, not zebras.
Updated October 24, 2026Reading time about 12 minGeneral information, not medical advice
Contents
Overview

At a glance

Often slow-growingMany NETs grow over years. Many people live with one for a long time, often while working and traveling.
A family of tumorsA NET in the lung behaves differently from one in the pancreas or intestine. Site and grade matter more than the label.
Usually managed long-termTreatment often aims at steady control over years, more like a chronic condition than a short fight.
Every case is differentOnly the care team knows the details of any one diagnosis. Let them, and the person diagnosed, guide what you hear.

Watch first

If you prefer to watch rather than read, these two short videos give a good introduction. Each opens on YouTube.

The basics

What a neuroendocrine tumor is

A NET is a growth that starts in neuroendocrine cells. These cells act like both nerve cells and hormone-making cells: they receive signals from the nervous system and respond by releasing hormones into the blood.

Neuroendocrine cells are found throughout the body but are most common in the digestive tract, the pancreas and the lungs. That is where most NETs begin.

  • Uncommon, and diagnosed more often than before. In the US, about 7 people per 100,000 were diagnosed each year as of 2012, up more than sixfold since 1973. Much of that rise reflects better scans and more frequent testing.
  • Often found late or by accident. Symptoms can be vague and are often mistaken for IBS, asthma or menopause. A long road to diagnosis is common and doesn't mean anyone missed something obvious.
  • "Carcinoid" is an older name. You may still hear it, especially for NETs of the gut and lungs.

Where NETs start

The place a NET begins is called the primary site. It shapes symptoms, treatment and outlook.

SiteYou may hearGood to know
Small intestineSmall bowel NET, midgut NETOne of the most common sites. More likely to cause carcinoid syndrome once it reaches the liver.
LungBronchial NET, typical or atypical carcinoidThe largest single site. Typical carcinoids are usually slow-growing.
PancreasPancreatic NET (pNET)A different disease from common pancreatic cancer (adenocarcinoma), with a very different outlook.
RectumRectal NETOften small and found during a routine colonoscopy.
AppendixAppendiceal NETOften found by chance after an appendix is removed.
StomachGastric NETSeveral subtypes, some very low-risk.
UnknownNET of unknown primarySometimes the starting point is never found. Treatment still goes ahead.

Grade and type

The grade describes how quickly the tumor cells are dividing. A lab test called Ki-67 measures the share of cells that are actively dividing, and that number sets the grade under the World Health Organization system.

NET or NEC?

Well-differentiated tumors look fairly like normal cells and are called NETs, at any grade. Poorly differentiated tumors are called neuroendocrine carcinomas (NECs). NECs are a separate disease. They grow faster and are treated more like small-cell lung cancer. A Grade 3 NET and an NEC can both have a Ki-67 over 20%, but they are not the same thing.

Functional or non-functional?

  • Functional tumors release enough hormones to cause symptoms.
  • Non-functional tumors don't. They are often found only when they grow or show up on a scan done for another reason.

Stage

Stage is separate from grade. It describes how far the tumor has spread: only where it started, to nearby lymph nodes, or to distant organs such as the liver or bones. It is common for a NET to have reached the liver by the time it is found, and many people live well for years with that.

Symptoms

Symptoms depend on where the tumor is and whether it makes hormones. Some people have none at all. Tumor size or location can cause belly pain, bowel blockage, bleeding, coughing or wheezing (lung NETs), tiredness or weight loss.

Carcinoid syndrome

Fewer than 1 in 5 people with a NET develop carcinoid syndrome. It usually happens when a NET has spread to the liver and releases hormones such as serotonin into the bloodstream. Signs include:

  • Flushing: sudden redness and warmth of the face and neck, lasting seconds to minutes
  • Frequent, urgent diarrhea
  • Wheezing or shortness of breath, and belly cramps
  • Over time, possible damage to the heart valves (carcinoid heart disease). It affects more than a third of people with the syndrome, so doctors check with an echocardiogram.

Alcohol, spicy food, large meals, stress or hard exercise can trigger flushing. If someone with a NET passes on certain foods or drinks at gatherings, this may be why.

Pancreatic NETs that make hormones cause other patterns. An insulinoma causes low blood sugar (shakiness, sweating, confusion), and a gastrinoma causes stomach ulcers and reflux.

When to get urgent help

Severe flushing with low blood pressure, trouble breathing, a racing or irregular heartbeat, fainting or confusion can mean a carcinoid crisis. It most often happens during surgery or anesthesia, so the care team plans for it ahead of procedures. At home, call emergency services.

Tests and scans

Diagnosis combines a tissue sample, imaging and lab tests. The same tests repeat every few months to years afterward, so regular appointments and scans are a normal part of life with a NET.

TestWhat it isWhy it's done
BiopsyA small tissue sample examined under a microscopeConfirms a NET and gives the grade (Ki-67)
CT or MRIDetailed cross-section images. About CT scansShows size and spread. MRI is especially good for the liver.
DOTATATE PETA PET scan with a tracer (Ga-68 or Cu-64) that sticks to receptors on most NET cells. About the Ga-68 scanFinds NETs other scans miss, and shows whether receptor-targeted treatments are likely to work
Chromogranin A (CgA)Blood test for a protein NETs often releaseHelps track the disease over time; not specific on its own
5-HIAA24-hour urine test (some labs offer a blood version) for a serotonin breakdown productChecks for and tracks carcinoid syndrome. Certain foods must be avoided before the test.
EchocardiogramUltrasound of the heartScreens for carcinoid heart disease
A note on chromogranin A

Common heartburn medicines called proton pump inhibitors (omeprazole, pantoprazole and others) can falsely raise CgA, even at low doses. Make sure the care team knows about every medicine, including over-the-counter ones.

"Scanxiety," the stress in the days around a scan, is very common. A message or call on scan days is often appreciated.

Care

Treatment

When a NET is found before it has spread, surgery to remove it is often the main treatment, followed by regular check-up scans. When it has spread, treatment aims to slow growth, ease symptoms and protect quality of life, often for many years. Treatments are usually used one after another as needs change. The options have grown considerably in the last decade.

TreatmentWhat it doesTypically used for
SurgeryRemoves the primary tumor and, when possible, spread to lymph nodes or liverTumors that can be removed; preventing bowel blockage
Active surveillanceRegular scans without active treatmentSmall, slow, stable tumors. A deliberate choice, not "doing nothing."
Somatostatin analogs
octreotide · lanreotide
Monthly injections that calm hormone release and slow tumor growthCarcinoid syndrome and many well-differentiated NETs; often the first medicine
PRRT
Lu-177 dotatate
Radiation carried straight to NET cells through the same receptors the PET scan showsReceptor-positive NETs, now including some newly diagnosed higher-grade NETs. Approved for ages 12+.
Liver-directed therapyEmbolization, ablation or Y-90 radioembolization cut off blood supply to liver tumors or destroy themNETs that have spread mainly to the liver
Targeted pills
everolimus · sunitinib · cabozantinib
Block signals tumors use to growGrowing NETs. Sunitinib is for pancreatic NETs. Cabozantinib was approved in March 2025 for previously treated NETs.
Chemotherapy
CAPTEM · platinum-based
Kills fast-dividing cellsPancreatic NETs and higher-grade NETs (CAPTEM); NECs (platinum-based)
Symptom medicines
telotristat · enzymes
Control diarrhea and help digestionCarcinoid syndrome not controlled by injections alone; treatment side effects
  • Monthly injections are routine. Many people get a shot every four weeks for years. A ride or company on shot days can help.
  • Nutrition matters. These injections can lower vitamin B12, D and A levels, and carcinoid syndrome can lower niacin. A dietitian who knows NETs can help.
  • A NET specialist makes a difference. Because NETs are uncommon, care at a center with a dedicated NET team or tumor board is often recommended. Second opinions are normal and expected.
  • Clinical trials are an option at many stages, not only as a last resort.
What a specialist NET center offers

Centers with a dedicated NET program typically have a NET tumor board, where experts review each case together and plan treatment. They also offer expert pathology and imaging review, hormone testing for functional tumors, and access to clinical trials. Nurses, dietitians, social workers, psychologists and palliative care specialists often work alongside the doctors, with support for caregivers too. NANETS and the Neuroendocrine Cancer Foundation can help you find one.

Outlook

The outlook for NETs varies more than for most cancers, and on the whole it is better than many people expect. People with low-grade NETs that are found early and removed generally do well, with regular check-ups afterward. Many people whose NET has spread also live for many years.

Outlook depends mostly on grade, primary site, stage and how the tumor responds to treatment. US data show survival improving over time. Published survival figures come from people diagnosed years ago, before several of today's treatments existed, and they can't predict one person's course. It's best not to quote them to someone living with a NET.

Many people describe life with a NET as living with a chronic condition. Fatigue, digestive problems, frequent appointments and uncertainty are common. Many also say they feel unseen because they "look fine." An invisible illness is still an illness.

Is it hereditary?

Most NETs are not inherited. A minority, more often pancreatic NETs, are linked to inherited conditions:

  • MEN1 (multiple endocrine neoplasia type 1), the most common
  • Von Hippel-Lindau syndrome (VHL)
  • Neurofibromatosis type 1 (NF1)
  • Tuberous sclerosis complex (TSC)

The care team may suggest genetic testing, especially for a pancreatic NET, a diagnosis at a young age, several tumors, or a family history of related conditions. If a hereditary cause is found, close relatives would be offered genetic counseling and possibly testing.

Small-intestine NETs occur somewhat more often in close relatives of someone who has one, though the absolute risk stays low because these tumors are rare. If you are a parent, sibling or child and ever have ongoing flushing, diarrhea or unexplained belly pain, mention this family history to your doctor.

For family

How family and friends can help

The most useful support is specific, steady, and guided by what they want.

Usually helps

  • Offer something concrete: "Can I drive you to your scan Tuesday?"
  • Check in around scans and results, and follow their lead on how much to talk.
  • Help with meals, errands, kids, pets or yard work, especially after procedures.
  • Be flexible. Fatigue and symptoms can change plans at short notice.
  • Respect food and drink choices without comment.
  • Come to appointments as a note-taker, if they'd like.
  • Keep treating them as themselves. Talk about ordinary life too.

Usually doesn't

  • Sharing survival statistics or stories about other people's cancers.
  • Suggesting alternative treatments, diets or supplements. Some interact with NET treatments; anything new should go through the care team.
  • "At least it's the good kind of cancer." Slower doesn't mean easy.
  • Passing on health news without their permission.

Questions for the care team

If the person with a NET wants help preparing for appointments, these cover what matters most.

  1. Where did the tumor start, and has it spread?
  2. What is the grade and Ki-67? Is it a well-differentiated NET or an NEC?
  3. Is the tumor making hormones? Are any symptoms caused by them?
  4. Did the DOTATATE PET scan show uptake, and what does that mean for treatment?
  5. What is the goal of treatment right now: removing the tumor, controlling its growth, or easing symptoms?
  6. What are the options, and why is this one recommended first?
  7. How often will scans and blood tests be done, such as CgA?
  8. Is a NET specialist or tumor board reviewing the case?
  9. Should genetic testing be considered?
  10. Are there clinical trials that fit?
  11. Is a heart check (echocardiogram) needed?
  12. Which symptoms mean we should call right away, and who do we call after hours?
Awareness
If you hear hoofbeats, think horses, not zebras.
A saying taught in medical schools

Why the zebra?

Doctors are trained to look for the common explanation first. That's usually right, but NETs are the zebra: uncommon, and easy to mistake for IBS, asthma or menopause. The zebra is a reminder that the uncommon exists and shouldn't be overlooked.

It carries a second meaning too. Every zebra's stripe pattern is unique, much like a fingerprint, and no two people with a NET have exactly the same disease.

The Neuroendocrine Cancer Awareness Network adopted the zebra as its symbol in 2003, and it is now used by NET patients and organizations worldwide. People show support by wearing zebra stripes, especially on World NET Cancer Day, November 10. Read more about the zebra

Reference

Trusted resources

These organizations focus on NETs and offer plain-language guides, specialist directories and support groups.

Glossary of terms
5-HIAA
A breakdown product of serotonin, measured in urine or blood
Carcinoid
An older name for NETs, mainly of the gut and lungs
Carcinoid syndrome
Flushing, diarrhea and wheezing caused by hormones from a NET
Chromogranin A
A protein released by NET cells, measured in blood
Differentiation
How much tumor cells resemble normal cells
DOTATATE PET
A scan that finds NET cells through their somatostatin receptors
Embolization
Blocking a tumor's blood supply, usually in the liver
Functional
A tumor that releases enough hormones to cause symptoms
Grade
How fast tumor cells are dividing (G1, G2, G3)
Ki-67
A lab measure of the share of dividing cells, used to set the grade
Metastasis
Spread of the tumor to another part of the body
NEC
Neuroendocrine carcinoma, a poorly differentiated, faster-growing type
PRRT
Peptide receptor radionuclide therapy, radiation delivered to NET cells
Primary site
Where the tumor first started
Somatostatin analog
A drug such as octreotide or lanreotide that mimics a natural hormone to calm NETs
Stage
How far the tumor has spread

Sources

  1. Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017. pubmed.ncbi.nlm.nih.gov/28448665
  2. Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020. pubmed.ncbi.nlm.nih.gov/31433515
  3. National Cancer Institute. Gastrointestinal Neuroendocrine Tumors Treatment (PDQ), health professional version. cancer.gov
  4. Xu Z, et al. Perioperative carcinoid crisis: a systematic review and meta-analysis. Cancers 2022. pubmed.ncbi.nlm.nih.gov/35740631
  5. Octreotide acetate for injectable suspension, prescribing information. DailyMed. dailymed.nlm.nih.gov
  6. FDA. Lutetium Lu 177 dotatate approved for pediatric patients 12 years and older with GEP-NETs (April 2024). fda.gov
  7. Singh S, et al. First-line [177Lu]Lu-DOTA-TATE in newly diagnosed advanced grade 2 and 3 GEP-NETs (NETTER-2). Lancet 2024. pubmed.ncbi.nlm.nih.gov/38851203
  8. FDA. Cabozantinib approved for pNET and epNET (March 2025). fda.gov
  9. Sorbye H, et al. Vitamin deficiencies in patients on somatostatin analogs. 2020. pubmed.ncbi.nlm.nih.gov/32546236
  10. RadiologyInfo.org (RSNA/ACR). Body CT. radiologyinfo.org
  11. NETRF. Ga-68 Dotatate PET/CT Scan for Neuroendocrine Tumors. netrf.org
  12. Neuroendocrine Cancer Awareness Network. The Zebra. netcancerawareness.org
  13. Hereditary syndromes in neuroendocrine tumors (review). pubmed.ncbi.nlm.nih.gov/27075353; familial risk of small-intestine NETs. pubmed.ncbi.nlm.nih.gov/23500615
↑